Filtered By:
Specialty: Drugs & Pharmacology
Condition: Pain

This page shows you your search results in order of date.

Order by Relevance | Date

Total 38 results found since Jan 2013.

Targeting the chemokine ligand 2-chemokine receptor 2 axis provides the possibility of immunotherapy in chronic pain
Eur J Pharmacol. 2023 Mar 10:175646. doi: 10.1016/j.ejphar.2023.175646. Online ahead of print.ABSTRACTChronic pain affects patients' physical and psychological health and quality of life, entailing a tremendous public health challenge. Currently, drugs for chronic pain are usually associated with a large number of side effects and poor efficacy. Chemokines in the neuroimmune interface combine with their receptors to regulate inflammation or mediate neuroinflammation in the peripheral and central nervous system. Targeting chemokines and their receptor-mediated neuroinflammation is an effective means to treat chronic pain. I...
Source: European Journal of Pharmacology - March 12, 2023 Category: Drugs & Pharmacology Authors: Shan Liu Xiao-Bing Lan Miao-Miao Tian Chun-Hao Zhu Lin Ma Jia-Mei Yang Juan Du Ping Zheng Jian-Qiang Yu Ning Liu Source Type: research

Downregulation of nuclear STAT2 protein in the spinal dorsal horn is involved in neuropathic pain following chronic constriction injury of the rat sciatic nerve
In this study, we investigated whether the transcription factor STAT2 affects neuropathic pain and evaluated its possible mechanisms. A proteomic analysis showed that the nuclear fraction of STAT2 protein in the SDH was downregulated after chronic constriction injury of the rat sciatic nerve, which was associated with the development of neuropathic pain. Similarly, siRNA-induced downregulation of STAT2 in the SDH of naïve rats also resulted in pain hypersensitivity. Using RNA-sequencing analysis, we showed that reduction of nuclear STAT2 after chronic constriction injury was associated with increased expression of microgl...
Source: Frontiers in Pharmacology - January 18, 2023 Category: Drugs & Pharmacology Source Type: research

14-3-3 γ mediates the long-term inhibition of peripheral kappa opioid receptor antinociceptive signaling by norbinaltorphimine
Neuropharmacology. 2022 Sep 17:109251. doi: 10.1016/j.neuropharm.2022.109251. Online ahead of print.ABSTRACTLong-term inhibition of kappa opioid receptor (KOR) signaling in peripheral pain-sensing neurons is a potential obstacle for development of peripherally-restricted KOR agonists that produce analgesia. Such a long-term inhibitory mechanism is invoked from activation of c-Jun N-terminal kinase (JNK) that follows a single injection of the KOR antagonist norbinaltorphimine (norBNI). This effect requires protein synthesis of an unknown mediator in peripheral pain-sensing neurons. Using 2D difference gel electrophoresis wi...
Source: Neuropharmacology - September 20, 2022 Category: Drugs & Pharmacology Authors: Michael J Wedemeyer Elaine M Jennings Hudson R Smith Teresa S Chavera Raehannah J Jamshidi Kelly A Berg William P Clarke Source Type: research

LncRNA MRAK159688 facilitates morphine tolerance by promoting REST-mediated inhibition of mu opioid receptor in rats
Neuropharmacology. 2022 Jan 1;206:108938. doi: 10.1016/j.neuropharm.2021.108938. Online ahead of print.ABSTRACTMorphine tolerance (MT) caused by the long-term use of morphine is a major medical problem. The molecular mechanism of morphine tolerance remains elusive. Here, we established a morphine tolerance model in rats and verified whether the long noncoding RNA (lncRNA) MRAK159688 is involved in morphine tolerance and its specific molecular mechanism. We show the significant upregulation of MRAK159688 expression in the spinal cord of morphine-tolerant rats. Overexpression of MRAK159688 by a lentivirus reduces the analges...
Source: Neuropharmacology - January 4, 2022 Category: Drugs & Pharmacology Authors: Meiling Deng Zengli Zhang Manyu Xing Xia Liang Zhengyiqi Li Jing Wu Shasha Jiang Yingqi Weng Qulian Guo Wangyuan Zou Source Type: research

The role of dorsal root ganglia alpha-7 nicotinic acetylcholine receptor in complete Freund ’s adjuvant-induced chronic inflammatory pain
ConclusionsThe findings of this study suggest that α7 nAChR may be potentially utilized as a therapeutic target for therapeutics of chronic inflammatory pain.
Source: Inflammopharmacology - September 12, 2021 Category: Drugs & Pharmacology Source Type: research

Givosiran: A Review in Acute Hepatic Porphyria
AbstractGivosiran (Givlaari®) is an δ-aminolevulinic acid synthase 1 (ALAS1)-directed small interfering RNA (siRNA) approved for the treatment of acute hepatic porphyria (AHP). In the phase 3 ENVISION trial, givosiran significantly reduced the annualized rate of composite porphyria attacks (i.e. attacks requiring hospitalization, urg ent healthcare visit or intravenous hemin administration at home) compared with placebo in patients with recurrent acute intermittent porphyria (the most common type of AHP) attacks. Givosiran also improved several other outcomes, including hemin use and pain (the cardinal symptom of AHP). W...
Source: Drugs - April 19, 2021 Category: Drugs & Pharmacology Source Type: research

Role of Calcitonin Gene-Related Peptide in Nociceptive Modulationin Anterior Cingulate Cortex of Na ïve Rats and Rats With Inflammatory Pain
It is known that calcitonin gene-related peptide (CGRP) plays a key role in pain modulation in the brain. There are high expressions of CGRP and CGRP receptor in anterior cingulate cortex (ACC), an important brain structure in pain modulation. The present study explored the role and mechanisms of CGRP and CGRP receptor in nociceptive modulation in ACC in naïve rats and inflammatory rats. Administration of different does of CGRP in ACC induced significant antinociception in a dose-dependent manner in both naïve rats and rats with inflammatory pain. The CGRP-induced antinociception was attenuated by injection of the CGRP r...
Source: Frontiers in Pharmacology - June 25, 2020 Category: Drugs & Pharmacology Source Type: research

New approaches to tumour therapy with siRNA-decorated and chitosan-modified PLGA nanoparticles.
Conclusions: The formulation we developed is a potential carrier system for both treatment of cancer and prevention of pain, especially for metastatic cancers. PMID: 31491363 [PubMed - as supplied by publisher]
Source: Drug Development and Industrial Pharmacy - September 8, 2019 Category: Drugs & Pharmacology Tags: Drug Dev Ind Pharm Source Type: research

The modulation of endometriosis by lncRNA MALAT1 via NF- κB/iNOS.
CONCLUSIONS: LncRNA MALAT1 can facilitate endometrial cell apoptosis and modulate MMP-9 expression via NF-κB/iNOS pathway, thus, mediating Ems pathogenesis. PMID: 31173276 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - June 9, 2019 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

Blockade of spinal α5-GABAA receptors differentially reduces reserpine-induced fibromyalgia-type pain in female rats.
Abstract The role of spinal α5 subunit-containing GABAA (α5-GABAA) receptors in chronic pain is controversial. The purpose of this study was to investigate the participation of spinal α5-GABAA receptors in the reserpine-induced pain model. Reserpine administration induced tactile allodynia and muscle hyperalgesia in female and male rats. Intrathecal injection of L-655,708 and TB 21007 (7 days after the last reserpine injection) decreased tactile allodynia and, at a lesser extent, muscle hyperalgesia in female rats. The effects of these drugs produced a lower antiallodynic and antihyperalgesic effect in male tha...
Source: European Journal of Pharmacology - June 6, 2019 Category: Drugs & Pharmacology Authors: De la Luz-Cuellar YE, Rodríguez-Palma EJ, Franco-Enzástiga Ú, Salinas-Abarca AB, Delgado-Lezama R, Granados-Soto V Tags: Eur J Pharmacol Source Type: research

A Bcr-Abl Inhibitor GNF-2 Attenuates Inflammatory Activation of Glia and Chronic Pain
GNF-2 is an allosteric inhibitor of Bcr-Abl. It was developed as a new class of anti-cancer drug to treat resistant chronic myelogenous leukemia. Recent studies suggest that c-Abl inhibition would provide a neuroprotective effect in animal models of Parkinson’s disease as well as in clinical trials. However, the role of c-Abl and effects of GNF-2 in glia-mediated neuroinflammation or pain hypersensitivity has not been investigated. Thus, in the present study, we tested the hypothesis that c-Abl inhibition by GNF-2 may attenuate the inflammatory activation of glia and the ensuing pain behaviors in animal models. Our resul...
Source: Frontiers in Pharmacology - May 19, 2019 Category: Drugs & Pharmacology Source Type: research